Skip to main content

Oncotelic Therapeutics, Inc. (OTLC)

OTCMKTS: OTLC · IEX Real-Time Price · USD
0.1200 -0.0100 (-7.69%)
Oct 20, 2021 3:43 PM EDT - Market closed
Market Cap46.27M
Revenue (ttm)n/a
Net Income (ttm)-11.46M
Shares Out369.55M
EPS (ttm)-0.03
PE Ration/a
Forward PE12.97
Dividendn/a
Ex-Dividend Daten/a
Volume104,517
Open0.1230
Previous Close0.1300
Day's Range0.1151 - 0.1290
52-Week Range0.0900 - 0.3800
Beta0.04
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About OTLC

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the ...

IndustryBiotechnology
IPO DateAug 26, 1993
Employees16
Stock ExchangeOTCMKTS
Ticker SymbolOTLC
Full Company Profile

Financial Performance

Financial Statements

News

MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS

AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phas...

7 months ago - GlobeNewsWire

MATEON'S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT

7 months ago - GlobeNewsWire

MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA'S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION ...

AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respirato...

7 months ago - GlobeNewsWire

MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™

AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) --  Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respirat...

8 months ago - GlobeNewsWire

MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA

AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced t...

8 months ago - GlobeNewsWire

MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™

AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announce to...

8 months ago - GlobeNewsWire

MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT

AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced t...

8 months ago - GlobeNewsWire

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive int...

9 months ago - GlobeNewsWire

MATEON'S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT

AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has enrolled and treated its first sentinel Part 1 pati...

9 months ago - GlobeNewsWire